

REMARKS

The specification has been amended to reflect the national stage status.

The claims have been amended to remove improper multiple dependencies.

Claim 28 has been amended to include a pharmaceutically acceptable carrier or diluent in conformance with U.S. practice. See page 73, line 13. Claims 29-33 and 35 are cancelled without prejudice since a use limitation bears no patentable weight in U.S. practice and such claims are duplicative of claim 28. Claims 36-37 have been revised in conformance with U.S. practice. New claim 42 has been added for additional patent protection.


Favorable action on the merits is solicited.

**THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEES FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975**

Respectfully submitted,

Hitoshi MURAI et al.

By



Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/dlk
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
February 10, 2005